Bone biology and physiology: Implications for novel osteoblastic osteosarcoma treatments?

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 281-286

  Spangler, John G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENYLATE CYCLASE; ALPHA 1 ADRENERGIC RECEPTOR; AMANTADINE; BONE MORPHOGENETIC PROTEIN; BROMOCRIPTINE; CAFFEINE; CALCIUM; CLOMIFENE; CYCLIC AMP; DEXAMETHASONE; DEXTROMETHORPHAN; DOXAZOSIN; ECONAZOLE; ESTRADIOL; INOSITOL; MEMANTINE; MICONAZOLE; N METHYL DEXTRO ASPARTIC ACID; NICOTINE; PRAZOSIN; ROFLUMILAST; ROLIPRAM; ROSIGLITAZONE; TAMOXIFEN; TERAZOSIN; TETOMILAST; THEOPHYLLINE; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE FRAGILITY; BONE METABOLISM; BONE REMODELING; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYME CELL; METASTASIS; OSTEOBLAST; OSTEOLYSIS; OSTEOSARCOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT INDICATION;

BONE NEOPLASMS; BONE REMODELING; CAFFEINE; CALCIUM; CELL LINE, TUMOR; CYCLIC AMP; CYTOKINES; HUMANS; MODELS, BIOLOGICAL; NICOTINE; OSTEOBLASTS; OSTEOSARCOMA; RECEPTORS, ADRENERGIC; RECEPTORS, GLUTAMATE; THIAZOLIDINEDIONES;

EID: 37349122106     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.013     Document Type: Article

References (41)

1. Hayden J.B., and Hoang B.H. Osteosarcoma: Basic science and clinical implications. Orthop Clin N AM 37 (2006) 1-7
2. Weinstein R.S., and Manolagas S.C. Apoptosis and osteoporosis. Am J Med 108 (2000) 153-164
3. Katagiri T., and Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8 (2002) 147-159
4. Jorgensen N.R. Short-range intercellular calcium signaling in bone. APMIS Suppl. 118 (2005) 5-36
5. Kirkwood K.L., Dziak R., and Bradford P.G. Inositol trisphosphate receptor gene expression and hormonal regulation in osteoblast-like cell lines and primary osteoblastic cell cultures. J Bone Miner Res 11 12 (1996) 1889-1896
6. 2+ from extra- and intracellular pools in osteoblastic cells. Am J Physiol Endocrinol Metab 257 (1989) E797-E803
7. Hiruma Y., Inoue A., Shiohama A., Otsuka E., Hirose S., Yamaguchi A., et al. Endothelins inhibit the mineralization of osteoblastic MC3T3-E1 cells through the A-type endothelin receptor. Am J Physiol Regul Integr Comp Physiol 275 (1998) R1099-R1105
8. 2+ Movement and Cytotoxicity in Human MG63 Osteosarcoma Cells. Pharmcol toxicol 95 (2004) 59-65
9. 2+ concentrations in human osteosarcoma cells. Hum Exp Toxicol 24 9 (2005) 453-458
10. 2+ levels and proliferation in human osteosarcoma cells. Life Sci 76 (2005) 2091-2101
11. 2+ mobilization in MG63 human osteosarcoma cells. Hormone Res 55 (2001) 265-270
12. 2+ entry in MG63 human osteosarcoma cells. Biochem Pharmacol 61 (2001) 1537-1541
13. 2+ movement in human osteosarcoma cells. Pharmacol Toxicol 91 (2002) 34-39
14. i increases in human osteoblast-like cells. Chin J Physiol 44 (2001) 67-72
15. 2+ levels in MG63 human osteosarcoma cells. Toxicol Lett 119 (2001) 227-233
16. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 58 2 (2002) 77-84
17. Suzuki A., Palmer G., Bonjour J.-P., and Caverzasio J. Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 140 (1999) 3177-3182
18. Gu Y., Genever P.G., Skerry T.M., and Publicover S.J. The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors. Calcif Tis Internat 70 (2002) 194-203
19. Rainesalo S., Keranen T., Saransaari P., and Honkaniemi J. GABA and glutamate transporters are expressed in human platelets. Brain Res Mol Brain Res 141 (2005) 161-165
20. Dickman K.G., Youssef J.G., Mathew S.M., and Said S.I. Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. Am J Respir Cell Mol Biol (2004) 139-144
21. Chenu C. Glutamatergic regulation of bone resorption. J Musculoskel Neuronal Interact 2 (2002) 423-431
22. Hinoi E., Fujimori S., and Yoneda Y. Modulation of cellular differentiation by N-methyl-d-aspartate receptors in osteoblasts. FASEB 17 (2003) 1532-1534
23. Wang Z.G., Liang J., Schellander K., Wagner E.F., and Grigoriadis A.E. C-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res 55 (1995) 6244-6251
24. Hinoi E., Takarada T., and Yoneda Y. Glutamate signaling system in bone. Pharmacol Sci 94 (2004) 215-220
25. Park Y.G., Kang S.K., Kim W.J., Lee Y.C., and Kim C.H. Effects of TGF-beta, TNF-alpha, IL-beta and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells. Int J Biochem Cell Biol 36 (2004) 2270-2280
26. Bradford P.G., Maglich J.M., and Kirkwood K.L. IL-1 beta increases type 1 inositol trisphosphate receptor expression and IL-6 secretory capacity in osteoblastic cell cultures. Mol Cell Biol Res Commun 3 (2000) 73-75
27. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., and Lecka-Czernik B. Bone is a target for the antidiabetic compound, rosiglitazone. Endocrinol 145 (2004) 401-406
28. Afsham Ali A., Weinstein R.S., Stewart S.A., Parfitt M., Manolagas S.C., and Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinol 146 (2004) 1226-1235
29. Majewska M.D., Bell J.A., and London E.D. Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate. Brain Res 537 (1990) 328-332
30. Tanaka H., Tanabe N., Suzuki N., Shoji M., Torigoe H., Sugaya A., et al. Nicotine affects mineralized nodule formation by the human osteosarcoma cell line Saos-2. Life Sci 77 (2005) 2273-2284
31. Broulik P.D., and Jarab J. The effect of chronic nicotine administration on bone mineral content in mice. Horm Metab Res 4 (1993) 219-221
32. Gullihorn L., Karpman R., and Lippiello L. Differential effects of nicotine and smoke condensate on bone cell metabolic activity. J Orthop Trauma 19 (2005) 17-22
33. Syversen U., Nordsletten L., Falch J.A., Madsen J.E., Nilsen O.G., and Waldum H.L. Effect of lifelong nicotine inhalation on bone mass and mechanical properties in female rat femurs. Calcif Tissue Int 65 (1999) 246-249
34. Walker L.M., Preston M.R., Magnay J.L., Thomas P.B., and El Haj A.J. Nicotinic regulation of c-fos and osteopontin expression in human-derived osteoblast-like cells and human trabecular bone organ culture. Bone 28 (2001) 603-608
35. Fang M.A., Frost P.J., Iida-Klein A., and Hahn T.J. Effects of nicotine on cellular function in UMR 106-01 osteoblast-like cells. Bone 12 (1991) 283-286
36. Yuhara S., Kasagi S., Inoue A., Otsuka E., Hirose S., and Hagiwara H. Effects of nicotine on cultured cells suggest that it can influence the formation and resorption of bone. Eur J Pharmacol 383 (1999) 387-393
37. Gullihorn L., Karpman R., and Lippiello L. Differential effects of nicotine and smoke condensate on bone cell metabolic activity. J Orthop Trauma 19 (2005) 17-22
38. Ahlstrom M., Pekkinen M., Huttunen M., and Lamberg-Allardt C. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol 69 (2005) 267-275
39. Narita M., Murata T., Shimizu K., Sugiyama T., Nakagawa T., Manganiello V.C., et al. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. Anticancer Drugs 14 (2003) 377-381
40. Kalariti N., Lembessis P., and Koutsilieris M. Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24 (2004) 3923-3929
41. Togari A., Arai M., Mizutani S., Mizutani S., Koshihara Y., and Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233 (1997) 125-128